优化急性髓系白血病自体干细胞移植的预处理方案:在首次完全缓解的高危患者中,白消安联合美法仑较白消安联合环磷酰胺结局更优:来自EBMT急性白血病工作组的研究
该研究纳入2000年1月至2016年12月首次完全缓解期接受自体移植的原发性急性髓系白血病成年患者,比较白消安联合美法仑(BUMEL)与白消安联合环磷酰胺(BUCY)的结局。在高危组(不良细胞遗传学和/或FLT3-ITD突变),BUMEL较BUCY降低5年复发率、改善无白血病生存和总生存;非高危组两方案无显著差异。
要点
- 高危组BUMEL较BUCY降低5年复发率(53% vs 69%),改善无白血病生存(42% vs 25%)和总生存(54% vs 36%)。
- 非高危组两方案5年复发率、无白血病生存和总生存均无显著差异。
- 作者结论:BUMEL是高危白血病患者更优的预处理方案,非高危患者两方案均有效。
核心结论
- BUMEL是高危白血病患者更优的预处理方案,而在无不良细胞遗传学或FLT3突变的急性髓系白血病患者中两种预处理方案均有效。
研究设计与样本
- 来自EBMT急性白血病工作组的较大规模研究,纳入2000年1月至2016年12月首次完全缓解期接受自体移植的原发性急性髓系白血病成年患者,且有可用的细胞遗传学资料。
- 1137例患者接受BUCY,512例接受BUMEL;两预处理组分布有差异的所有因素均纳入多因素分析。
主要发现
- 主要分析发现预处理方案与高危组(不良细胞遗传学和/或FLT3-ITD突变)之间存在交互作用。
- 高危组分析中,176例接受BUCY,62例接受BUMEL;BUMEL与5年复发率较低相关(53% vs 69%,HR:0.52,P=0.002)。
- 高危组中BUMEL与更好的无白血病生存相关(42% vs 25%,HR:0.54,P=0.002),与更好的总生存相关(54% vs 36%,HR:0.61,P=0.02)。
- 非高危组分析中,961例接受BUCY,450例接受BUMEL;5年复发率分别为50%和47%,无白血病生存分别为45%和48%,总生存分别为56%和60%,均无显著差异。
关键数值与推荐
- 高危组:BUMEL较BUCY的5年复发率53% vs 69%(HR:0.52,P=0.002)。
- 高危组:BUMEL较BUCY的无白血病生存42% vs 25%(HR:0.54,P=0.002)。
- 高危组:BUMEL较BUCY的总生存54% vs 36%(HR:0.61,P=0.02)。
- 非高危组:BUCY与BUMEL的5年复发率50% vs 47%,无白血病生存45% vs 48%,总生存56% vs 60%,均无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous stem cell transplantation remains a clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a small cohort of patients, we have previously shown better outcomes following Busulfan and Melphalan (BUMEL) over Busulfan and Cyclophosphamide (BUCY). To identify the subpopulations that might get the highest benefit with BUMEL, we designed a larger study. All adult patients with primary AML and available cytogenetics, autografted from January 2000 to December 2016 in CR1, were included: 1137 patients received BUCY and 512 BUMEL. All factors differing in distribution between the 2 conditioning groups were introduced in multivariate analyzes. In a primary analysis, we found an interaction between conditioning and the poor risk group defined as poor cytogenetics and/or presence of the FLT3-ITD mutation. During analysis of the poor risk group, 176 patients received BUCY and 62 BUMEL. BUMEL was associated with a lower RI at 5 years (53% versus 69%, HR: 0.52, P = .002), a better Leukaemia-free survival (LFS) (42% versus 25%, HR: 0.54, P = .002) and a better OS (54% versus 36%, HR: 0.61, P = .02). During analysis of the non poor risk group, 961 patients received BUCY and 450 BUMEL. At 5 years, the RI was 50% and 47%, the LFS 45% and 48% and the OS 56% and 60% respectively, with no significant difference. We conclude that BUMEL is the preferable conditioning regimen for the poor risk leukemic patients, while in AML patients without poor risk cytogenetics or FLT3 both conditioning regimens are valid.
引用
- Gorin NC, Labopin M, Blaise D, et al. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. Am J Hematol. 2018. PMID: 29644709. doi:10.1002/ajh.25105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。